Robert LeBoyer
Stock Analyst at Noble Capital Markets
(1.86)
# 3,009
Out of 4,711 analysts
16
Total ratings
35.71%
Success rate
5.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOVX GeoVax Labs | Maintains: Outperform | $6 → $10 | $2.29 | +336.68% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $6 | $0.68 | +777.19% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $16.17 | +271.06% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $4.36 | +129.36% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $2.02 | +593.07% | 1 | Feb 21, 2023 | |
| TNXP Tonix Pharmaceuticals Holding | Initiates: Outperform | $3,840 | $0.61 | +627,761.35% | 1 | Apr 18, 2022 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $0.56 | +1,333.69% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $120 | $1.09 | +10,909.17% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $11.41 | - | 1 | Oct 5, 2020 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $12 | $8.63 | +39.05% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16,500 | $0.11 | +15,277,677.78% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.96 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $5.31 | +182.49% | 2 | Mar 8, 2018 |
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6 → $10
Current: $2.29
Upside: +336.68%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $6
Current: $0.68
Upside: +777.19%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $16.17
Upside: +271.06%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $4.36
Upside: +129.36%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $2.02
Upside: +593.07%
Tonix Pharmaceuticals Holding
Apr 18, 2022
Initiates: Outperform
Price Target: $3,840
Current: $0.61
Upside: +627,761.35%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $0.56
Upside: +1,333.69%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $1.09
Upside: +10,909.17%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $11.41
Upside: -
Anavex Life Sciences
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $8.63
Upside: +39.05%
Aug 24, 2020
Initiates: Buy
Price Target: $16,500
Current: $0.11
Upside: +15,277,677.78%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $14.96
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $5.31
Upside: +182.49%